The case, published in BMC Psychiatry by a team led by Aditya Shrivastav of Datta Meghe Institute of Medical Sciences in India, is a striking real-world illustration of the nocebo effect — the dark twin of the placebo response, in which negative expectations about a treatment actively generate the very symptoms a patient fears. Where placebo heals through belief, nocebo harms through it. And in an era when anyone starting a medication can spend an evening scrolling through forums and horror stories about its side effects, researchers argue the phenomenon is quietly sabotaging mental health treatment on a massive scale.

The clinical picture the woman presented was genuinely alarming. She had been diagnosed with moderate major depressive disorder, and sertraline — a selective serotonin reuptake inhibitor, or SSRI — was a reasonable, guideline-consistent choice. But within two days of the first tablet, the cardiopulmonary storm began. Emergency physicians found sinus tachycardia, a racing but otherwise structurally normal heart rhythm, with no ischemic changes on the electrocardiogram to suggest the heart muscle was being starved of oxygen. Serial cardiac biomarkers, the proteins that spill into the bloodstream when heart tissue dies during a heart attack, remained stubbornly within normal limits. There was no clot, no arrhythmia crisis, no metabolic derangement to explain what she was feeling.

Then the imaging added a twist that kept the case from being dismissed. A transthoracic echocardiogram — an ultrasound of the beating heart — showed borderline left ventricular systolic function, with an ejection fraction of 51 percent, just under the conventional threshold of normal, accompanied by mild diffuse global hypokinesia, a subtle generalized weakening of the heart’s contraction. A brain MRI ruled out acute intracranial pathology. In other words, something real was measurable in her body, but nothing pointed to the acute cardiac catastrophe her symptoms seemed to announce. The team treated her supportively, and the symptoms gradually resolved — a pattern more consistent with a transient, expectation-driven physiological storm than with structural heart disease.

The detective work that followed is what elevates this from an oddity to a teaching case. When clinicians sat down with the patient for detailed psychiatric reassessment, a crucial piece of history emerged: before taking her first dose, she had immersed herself in online information about antidepressant adverse effects. And the symptoms she had read about — palpitations, chest tightness, breathlessness, dizziness — matched, with uncomfortable precision, the symptoms she then experienced. Her body had not simply malfunctioned. In a very real physiological sense, it had performed the script she had absorbed, translating anticipation of harm into autonomic arousal, hyperventilation, and cardiac symptoms indistinguishable from disease.

This is not metaphor; the nocebo effect has measurable biology. Expectation of a symptom activates the same neural circuitry that generates the symptom itself. Anticipatory anxiety drives sympathetic nervous system activation — adrenaline release, elevated heart rate, heightened interoceptive attention, the brain’s monitoring of internal bodily signals turned up to maximum gain. A person primed to detect palpitations will notice every benign flutter and interpret it as evidence of danger, which spikes anxiety further, which amplifies the sensation, in a self-reinforcing loop that can produce chest pain, hyperventilation, and genuine, measurable cardiovascular changes. The mind does not imagine the symptom. It manufactures it, through the same machinery that produces any other bodily experience.

What happened next is the part that should make every prescriber sit up. Rather than abandoning sertraline permanently — the fate of an estimated substantial fraction of patients who quit antidepressants in the first weeks because of early side effects — the team pursued a strategy of structured psychoeducation and expectation-targeted counselling. The patient was walked through what the medication actually does, what early effects are common and transient, and, critically, how expectation itself can generate symptoms. Then came the experiment that mattered: sertraline was reintroduced at a lower dose. This time, there was no recurrence of the cardiopulmonary symptoms. Same drug, same patient, same body — different expectations.

The five-week follow-up sealed the narrative. A repeat echocardiogram showed her left ventricular function had normalized entirely, with the ejection fraction rising to 58 percent. Her depression, measured on the 17-item Hamilton Depression Rating Scale, had fallen from 21 — firmly in the severe range — to 10, a substantial clinical improvement. The medication she had nearly lost to fear was, once fear was managed, doing exactly what it was prescribed to do. The authors are appropriately careful: a single case report cannot establish causality, and early genuine pharmacological effects of SSRIs cannot be completely excluded. But the absence of symptom recurrence after a psychoeducation-guided rechallenge is a powerful circumstantial fingerprint of an expectation-driven mechanism.

The broader implications reach well beyond one woman and one antidepressant. Adherence to psychiatric medication is a chronic, global problem, and the first two weeks of SSRI therapy are where most patients are lost — the window in which early side effects, real or expected, collide with a person who has not yet felt any benefit. The authors argue that recognition of nocebo phenomena, careful counselling, and proactive expectation management before the first tablet is swallowed could keep patients on effective treatment, spare emergency departments the cost of cascades of unnecessary cardiac workups, and prevent the premature discontinuation of medications that work. In an information environment where a search for any drug’s name surfaces its worst outcomes first, the prescription may increasingly need a companion: a conversation about what the internet has already told you, and what your own anticipating brain can do with it.

There is also a caution here for the rest of us, the patients rather than the prescribers. The case does not suggest symptoms are imaginary or that people should dismiss what their bodies tell them — this woman’s chest pain warranted a full emergency evaluation, and she received one, and that was the right call. What it suggests is that the mind is not a passive observer of pharmacology. It is a participant, sometimes a saboteur, capable of summoning the side effects it dreads most. The first dose of a medication, it turns out, is taken twice: once by the body, and once — often hours earlier, on a screen, in the dark — by the imagination. Only one of those doses comes with a dosage instruction.

Subject of Research: A nocebo effect case report in which expectation-driven cardiopulmonary symptoms after sertraline initiation mimicked acute cardiac pathology

Article Title: Nocebo-induced cardiopulmonary symptoms following sertraline initiation mimicking acute cardiac pathology: a case report

Article References: Shrivastav, A., Tivaskar, S., Luharia, A., & Mishra, G. (2026). Nocebo-induced cardiopulmonary symptoms following sertraline initiation mimicking acute cardiac pathology: a case report. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08525-9

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08525-9

Keywords: nocebo effect, sertraline, SSRI, placebo effect, major depressive disorder, cardiopulmonary symptoms, medication adherence, psychoeducation, treatment expectations, psychiatry, case report, antidepressants

Against that backdrop, a clinical trial led by Honey and colleagues attracted significant attention when it reported the first prospective evaluation of deep brain stimulation of the ventral intermediate nucleus of the thalamus, or Vim-DBS, as a treatment for laryngeal dystonia. The phase I study enrolled six patients with laryngeal dystonia and co-occurring voice tremor in a randomized, double-blind, cross-over design. One group received three months of active stimulation followed by three months without it, while the other group followed the reverse sequence. Outcomes were measured with the Voice-Related Quality of Life questionnaire, the Voice Handicap Index, and the Unified Spasmodic Dysphonia Rating Scale. Now, a multidisciplinary team of specialists in neurology, neurosurgery, otolaryngology, and speech science has published a pointed commentary in the journal Dystonia arguing that the trial’s conclusions deserve far more caution than they have received.

The commentary, authored by Lena C. O’Flynn, Giovanni Battistella, Kristina Simonyan, and colleagues from institutions including Harvard Medical School, University Hospital Cologne, Tokyo Women’s Medical University, and University College London, identifies fundamental flaws in the trial’s methodology. Although the study was designed as a double-blind investigation, the authors report that all six patients became aware of the blinded sequence during the study, effectively rendering the blinding unsuccessful. Moreover, patients appear to have been retrospectively asked to guess which group they had been assigned to, a procedure not defined in the study’s clinical protocol. Because the cross-over design also lacked a wash-out period between the stimulation-on and stimulation-off conditions, the effects of each condition were likely contaminated by carryover from the other. Taken together, these failures effectively reclassified the trial as an open-label study, yet the outcomes were discussed as if patients had participated in a rigorously blinded cross-over design.

The stakes of such design failures are considerable. Invasive interventions such as deep brain stimulation are associated with placebo effects exceeding 50 percent, substantially stronger than those seen with non-invasive treatments, according to prior systematic reviews of surgical placebo controls. When blinding collapses, the door opens wide for expectation effects to masquerade as therapeutic benefit. The commentary’s authors emphasize that adherence to the pre-registered clinical trial protocol is imperative, particularly when the intervention involves brain surgery and the patient population is one that is often desperate for new options.

Beyond the blinding problems, the commentary takes issue with the outcome measures themselves. The Voice-Related Quality of Life and Voice Handicap Index are patient-reported instruments that capture the impact of voice problems on wellbeing, but they do not differentiate between disorder-specific symptoms. A well-known clinical observation holds that quality of life and laryngeal dystonia severity do not necessarily correlate: patients with mild symptoms may experience greater quality-of-life burden than those with severe symptoms. The overall severity component of the Unified Spasmodic Dysphonia Rating Scale, meanwhile, is a compound score blending laryngeal dystonia-specific features such as roughness, breathiness, and strain with voice tremor measurements, without offering differential diagnostics. Because these tools lack specificity, the commentary argues, they may inaccurately assess symptom severity, and more specialized assessments of dystonia-characteristic voice breaks, harshness, strain, breathiness, and tremor have been recommended instead.

The statistical picture is equally troubling. The trial’s authors stated that every patient reported improvement in quality of life and voice quality, yet the reported p-values of 0.07 and 0.06 did not reach conventional thresholds for statistical significance, and one of the six patients experienced no symptom improvement at all. The commentary notes that this statement contradicts the actual outcome of the trial and represents an over-generalization of the findings. Furthermore, the published report deviated from the pre-registered protocol: the planned analysis of variance with Bonferroni-corrected pairwise comparisons was not carried out as specified, and the enrolled cohort included a patient outside the study’s eligible age range. The findings, in short, showed no statistically significant improvement of laryngeal dystonia voice symptoms following thalamic stimulation, a result consistent with previous reports that also failed to demonstrate significant therapeutic effects of Vim-DBS in this disorder.

A crucial confound, according to the commentary, is the presence of voice tremor. All six patients in the trial had voice tremor, and some also had essential tremor, yet the study did not separately address the effects of thalamic stimulation on tremor symptoms. This matters enormously because Vim-DBS has an established track record for tremor disorders: it has been the standard of care for medication-refractory essential tremor since receiving approval from the United States Food and Drug Administration in 1997, and the same research group has previously shown that both bilateral and unilateral thalamic stimulation significantly reduce voice tremor symptoms, findings since replicated by other teams. In light of the absence of differential classification between dystonic and tremulous voice symptoms, the commentary suggests that any reported changes in the trial may have been driven more by reductions in voice tremor than by improvements in laryngeal dystonia itself.

The commentary then points to a more scientifically justified target. Unlike tremor, dystonic symptoms respond most reliably to stimulation of the globus pallidus pars interna, or GPi, and the subthalamic nucleus, particularly in patients with drug-refractory cervical, segmental, and generalized dystonias. Clinical reports of GPi-DBS in laryngeal dystonia patients without voice tremor have shown therapeutic benefit with minimal adverse events. In one detailed study, researchers performed auditory-perceptual evaluations of voice and speech in dystonia patients following bilateral pallidal stimulation and documented significant improvements in overall grade, roughness, and strain at twelve months after surgery, highlighting a delayed but substantial therapeutic impact. Similar long-term improvements have been reported in patients with segmental dystonia and in patients with Meige syndrome. Most tellingly, a recent comparative investigation of GPi-DBS and Vim-DBS in patients with laryngeal dystonia and co-occurring voice tremor found that pallidal stimulation was superior in reducing dystonia-characteristic voice breaks and improving continuous voicing and overall speech intelligibility, whereas thalamic stimulation was most effective at reducing tremor intensity.

The commentary also scrutinizes a follow-up neuroimaging study from the same group, which used diffusion MRI tractography in the same six patients to identify a stimulation sweet spot and define individual biomarkers of DBS response. The researchers arbitrarily categorized individual electrode contacts as effective or ineffective without reporting statistical or numerical thresholds for that classification. The segmentation analysis found that effective contacts targeted thalamic areas linked to the sensorimotor region while ineffective contacts targeted areas connected to the prefrontal region, but these findings did not correlate with laryngeal dystonia symptom improvement, and no statistically significant sweet spot emerged. Nevertheless, the follow-up study concluded that stimulation of thalamic sensorimotor areas is associated with symptom improvement and claimed to have identified a novel biomarker for DBS targeting. The commentary’s authors argue that such claims should be interpreted with caution, as they neither identify the primary pathophysiological factors of laryngeal dystonia nor define the neural correlates of the stimulation response.

The bottom line, the commentary concludes, is that the negative results of this phase I trial do not support advancing to phase II investigations of thalamic deep brain stimulation for laryngeal dystonia. Given the invasiveness of brain surgery and the readiness of most patients with laryngeal dystonia to enroll in new treatments, the authors urge that these findings not be overinterpreted when designing future studies or making clinical neurosurgical decisions. They call for future trials to adhere to Good Clinical Practice guidelines, with strict adherence to predetermined inclusion criteria, a priori hypotheses, and statistical thresholds, along with rigorous power analyses to ensure adequate sample sizes. They also recommend that researchers clearly define the type of speech impairment under study, distinguish co-occurring disorders such as voice tremor, incorporate both objective acoustic measures and patient-reported outcomes, and share voice recordings and precise electrode contact locations and stimulation parameters to enable replication. For a disorder that robs patients of fluent speech, the path forward, the authors insist, must be built on methodological rigor rather than premature optimism.

Subject of Research: Deep brain stimulation targeting for laryngeal dystonia treatment

Article Title: Is thalamic deep brain stimulation the right target to improve laryngeal dystonia symptoms?

Article References: O’Flynn, L. C., Barbe, M. T., Horisawa, S., Barkmeier-Kraemer, J. M., Blitzer, A., Greenlee, J. D. W., Hamzei-Sichani, F., Moretti, P., Nagarajan, S. S., Sharma, N., Rahimpour, S., Rusz, J., Tripoliti, E., Battistella, G., & Simonyan, K. (2025). Is thalamic deep brain stimulation the right target to improve laryngeal dystonia symptoms?. Dystonia, 4, Article 15271. https://doi.org/10.3389/dyst.2025.15271

Image Credits: AI Generated

DOI: 10.3389/dyst.2025.15271

Keywords: laryngeal dystonia, spasmodic dysphonia, deep brain stimulation, ventral intermediate nucleus, globus pallidus interna, voice tremor, clinical trial methodology, botulinum toxin, dystonia, neuromodulation, placebo effect, voice outcomes

The trial, led by Mengyuan Li and colleagues at the University of Southern Queensland and partner institutions in Australia and China, enrolled 108 women who had completed chemotherapy for early-stage breast cancer between one month and three years earlier. Each participant reported at least moderate levels of fatigue, sleep disturbance and depression, scoring four or higher on a standard 0-to-10 rating scale. The women were randomly allocated in equal numbers to one of three groups: a true self-acupressure group, a sham self-acupressure group, or a usual care group. Ninety-three participants completed the study, with 31 in each arm, and the retention rate of 86 percent was notably strong for a trial of this length and population.

The intervention itself was elegantly simple. Women in the true acupressure group were trained in a 20-minute face-to-face session to apply firm pressure to eleven acupoints, seven of them bilateral, chosen for their traditional and emerging scientific relevance to fatigue, sleep and mood. These included well-known points such as Zusanli (ST36) on the lower leg, Neiguan (PC6) on the forearm, Shenmen (HT7) on the wrist, and Yintang (EX-HN3) between the eyebrows. Each point was stimulated for two minutes, adding up to a daily 36-minute practice continued for seven weeks. Participants in the sham group followed an identical regimen but pressed eleven non-acupoints located one to three centimetres away from the real points and deliberately off the classical meridians. Because both groups performed an active, plausible technique, neither the participants nor the self-rated outcome assessments could distinguish true from sham treatment, providing a rigorous test of whether acupressure’s benefits depend on stimulating specific points or simply on the ritual of self-care.

The results were unambiguous. Using a sophisticated statistical approach—generalised estimating equations with covariate selection guided by penalised regression—the researchers found significant group-by-time interactions for every clinical outcome. The true self-acupressure group showed substantially greater reductions in the composite symptom cluster score than both comparison groups, not only at the end of the seven-week intervention but also at the twelve-week follow-up, with large standardised effect sizes reaching as high as 2.33 against usual care. Crucially, the benefits were sustained: the advantage over the sham group actually grew over time, suggesting that continued practice deepened the therapeutic effect rather than fading like a placebo response.

At the level of individual symptoms, the pattern was equally compelling. Sleep disturbance, measured with the Pittsburgh Sleep Quality Index, and depression, measured with the Hospital Anxiety and Depression Scale, both improved significantly more in the true acupressure group than in either comparison group at both assessment points. Fatigue, measured with the Brief Fatigue Inventory, showed a large advantage over usual care throughout, while the difference between true and sham acupressure reached statistical significance only at the twelve-week follow-up. Quality of life, assessed with the Functional Assessment of Cancer Therapy-Breast instrument, rose markedly in the true acupressure group, with the gap over the sham group widening from a non-significant trend at week seven to a highly significant difference by week nineteen.

One of the most scientifically interesting findings concerns the sham group itself. Women who pressed non-acupoints also fared significantly better than those receiving usual care, with moderate effect sizes. The authors attribute this to placebo and psychosocial mechanisms: the strong desire for symptom relief, positive expectations, and the act of actively engaging in a daily self-care ritual can all modulate symptom perception through genuine psychological and physiological pathways. This does not diminish the value of the true intervention—whose effects were consistently larger and more durable—but it does highlight how much of symptom management in cancer survivorship may be harnessed through expectation and self-efficacy. The trial’s design, following a sham-controlled structure refined through an earlier phase II pilot study, allowed the researchers to separate these non-specific effects from the specific benefits of stimulating authentic acupoints.

Why might pressing specific points on the body influence fatigue, sleep and mood at all? The prevailing biological explanation for this symptom cluster is cytokine-induced sickness behaviour: cancer treatments trigger persistent low-grade inflammation, and pro-inflammatory signalling molecules act on the brain to produce the lethargy, sleep disruption and low mood that survivors describe. Non-pharmacological interventions such as exercise, acupuncture and acupressure have been shown in prior research to reduce circulating pro-inflammatory cytokines, offering a plausible mechanistic bridge. The trial’s authors acknowledge, however, that they did not directly measure cytokines in this study, leaving the precise biological pathway an open question for future work.

Safety and cost are where the findings become genuinely striking for clinical practice. Not a single adverse event was reported across the entire trial, a stark contrast to acupuncture, which carries small risks of infection and bruising due to its invasive nature, and to pharmacological approaches, which raise concerns about drug interactions in patients already on complex regimens. The economic picture was similarly favourable: during the trial, only one participant in the true acupressure group and one in the usual care group used healthcare resources for symptom relief, with total costs of 931.06 and 2,247.44 yuan respectively, while the only direct intervention cost was a one-off 2,879 yuan for producing instructional videos. The researchers caution that these numbers are too sparse for a formal cost-effectiveness analysis, but the direction of the data is hard to ignore.

The trial was not without limitations. All outcomes relied on self-reported questionnaires, which, although well-validated, are inherently subjective; the authors recommend that future studies incorporate objective measures such as actigraphy or inflammatory biomarkers. The composite cluster score assumed equal weighting of the three symptoms, and adherence to the full 49-day practice schedule was challenging, with only about 28 percent of the true acupressure group completing every day. Yet even partial adherence produced large effects, and the researchers suggest that real-world implementation could allow individualised adjustments to session length based on each woman’s energy and symptom burden.

The implications reach well beyond breast cancer. With more than 53 million people worldwide now living five or more years past a cancer diagnosis, accessible, self-managed strategies for the lingering burden of survivorship are urgently needed. Cognitive behavioural therapy demands multiple sessions with trained therapists; exercise programmes can be exhausting for women already depleted by fatigue. Self-acupressure, by contrast, requires only a short training, can be practised anywhere at any time, and costs almost nothing once learned. The authors argue that the intervention could be readily integrated into routine survivorship care and primary healthcare settings, particularly where professional resources are scarce. As the first fully powered phase III trial to demonstrate sustained, cluster-level benefits of self-acupressure in breast cancer survivors, the study transforms an ancient technique into a modern, evidence-based prescription—one that patients can literally hold in their own hands.

Subject of Research: Self-acupressure for managing the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors

Article Title: Effects of self-acupressure on the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors: a phase III randomised controlled trial

Article References: Li, M., Kwok, W. H., Wang, T., Deng, R., Wang, H., Yao, L., Deravin, L., Yang, L., Tian, X., & Tan, J.-Y. B. (2026). Effects of self-acupressure on the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors: a phase III randomised controlled trial. Supportive Care in Cancer, 34(10), Article 981. https://doi.org/10.1007/s00520-026-11155-2

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11155-2

Keywords: self-acupressure, breast cancer survivors, symptom cluster, fatigue, sleep disturbance, depression, randomised controlled trial, quality of life, traditional Chinese medicine, cancer survivorship, non-pharmacological intervention, placebo effect

The research drew on two of the largest biomarker studies in depression research: EMBARC, the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care trial conducted in the United States, and CAN-BIND-1, the Canadian Biomarker Integration Network in Depression. Together, the cohorts included 386 patients aged 18 to 65, with 257 women and 129 men. Participants were randomly assigned to receive the selective serotonin reuptake inhibitors sertraline or escitalopram, or a placebo, with 123 patients on sertraline, 138 on escitalopram and 125 on placebo. Crucially, each patient underwent resting-state functional MRI scans both before treatment and again after one to two weeks of medication, allowing the researchers to compute how thousands of pairwise connectivity relationships between brain regions changed as treatment began.

Functional connectivity, measured as the temporal correlation of spontaneous blood-oxygen-level-dependent signal between brain areas, provides a window into the brain’s intrinsic organization without requiring patients to perform any task. The team faced a familiar obstacle in this kind of data: the signal-to-noise ratio of individual connectivity edges is low, and naive machine learning models tend to latch onto features that do not replicate. To address this, the researchers developed an innovative analytical strategy combining predictive and contrastive machine learning frameworks, constrained to connectivity changes with sufficient reliability. The contrastive component allowed them to statistically disentangle effects that are common to all treated patients from effects specific to drug or to placebo, a decomposition that has rarely been attempted at this scale.

The first major finding was a universal signature. Regardless of whether patients received sertraline, escitalopram or placebo, and regardless of whether their symptoms ultimately improved, nearly all medicated patients showed increased connectivity within a system linking visual cortex, the precuneus and the thalamus. The precuneus, a hub of the brain’s default mode network implicated in self-referential thought and memory, and the thalamus, the brain’s central relay station, are both known to interact with visual processing regions. Earlier work has shown that placebo treatment can alter primary visual cortex activity and connectivity, and this new result places those observations within a much larger and more systematic framework. The consistency of this visual-precuneus-thalamus change across two independent cohorts suggests it reflects a generalizable response to entering pharmacological treatment for depression, not a drug-specific mechanism.

By contrast, the neural correlates of placebo-related symptom improvement were centered elsewhere. The study found that striatal and attention networks mediated the placebo-driven reduction in depressive symptoms. The striatum, a subcortical structure central to reward processing and motivational learning, has repeatedly been implicated in placebo phenomena, including a well-known finding that reward-related ventral striatal activity distinguishes sertraline responders from placebo responders. The involvement of attention networks aligns with the psychological literature on expectation, which holds that placebo effects arise when anticipation and attention reorient the brain’s evaluative machinery. In practical terms, patients whose early connectivity shifts in these networks were pronounced were the ones whose symptoms improved most from expectation and context, independent of any pharmacological action.

The true drug effects were narrower and more selective than many researchers expected. Connectivity changes specific to sertraline and escitalopram converged on the amygdala, the midcingulate cortex, the orbitofrontal cortex and the cerebellum. These are regions with wellestablished roles in emotional regulation and depression: the amygdala generates threat and salience responses, the orbitofrontal cortex evaluates reward and punishment, the midcingulate cortex integrates motivation and control, and the cerebellum, long dismissed as purely motor, is increasingly recognized as a participant in cognitive and affective circuitry, with altered cerebellar-cerebral connectivity reliably distinguishing patients with depression. Notably, these drug-specific changes appeared in only a subset of the patients actually taking antidepressants. Pharmacological treatment, in other words, leaves a detectable early neural fingerprint in some brains but not in others, a neural reflection of the heterogeneity that has always frustrated clinicians.

The most clinically consequential finding emerged from that heterogeneity. When patients on sertraline did not show the drug-specific amygdala, midcingulate, orbitofrontal or cerebellar connectivity changes, their responses could be predicted using a model trained on placebo response signatures. This implies that a substantial share of what looks like antidepressant response in the clinic may actually be placebo response occurring in medicated patients. Given that systematic reviews of antidepressant trials have long documented substantial and growing placebo response rates, this study provides a mechanistic account of why: expectation engages striatal and attentional circuitry, and patients who are predisposed to engage that circuitry will improve whether or not the drug’s molecular mechanisms take hold in their emotional-regulation circuits.

Methodologically, the study’s strength lies in its cross-cohort validation. Patterns identified in one cohort were tested in the other, and the universal visual-precuneus-thalamus changes, the placebo mediators and the drug-specific effects all replicated across the EMBARC and CAN-BIND-1 datasets, which used different scanners, sites and clinical protocols. The analysis pipeline itself was rigorous, employing established preprocessing tools including fMRIPrep, boundary-based registration, ICA-based motion artifact removal and standard strategies to control the spurious correlations introduced by subject head motion. The predictive models were evaluated with cross-validated Pearson correlations between predicted and observed symptom change, and hyperparameters governing sparsity were tuned to avoid overfitting. The code was released publicly through Code Ocean, and the EMBARC data are available through the National Institute of Mental Health Data Archive, inviting independent scrutiny.

The implications for patient care are considerable. Today, deciding whether an antidepressant is working typically requires six to eight weeks of observation, and roughly half of patients discontinue treatment early, often because of side effects before any benefit arrives. If early connectivity changes measured after one week could be incorporated into an interactive treatment optimization framework, clinicians could potentially distinguish, within days, patients whose brains are responding to the drug’s pharmacology from patients whose trajectory depends on placebo-related circuitry, who might instead benefit from psychotherapy, neuromodulation or placebo-enhanced care strategies. This aligns with a broader movement in psychiatry toward biosignature-guided treatment, including prior work from overlapping research groups demonstrating that electroencephalographic signatures and structure-function covariation patterns can predict antidepressant response.

Important caveats remain. The study examined only two serotonergic medications over a brief window, and it remains unknown whether the same signatures generalize to other antidepressant classes, to longer treatment durations, or to adolescent and older populations. Resting-state fMRI measures indirect hemodynamic activity rather than neural firing, and even carefully denoised connectivity estimates carry residual uncertainty at the individual level. The authors also note that drug-specific connectivity changes were present in a subset rather than all medicated responders, so the absence of such changes does not guarantee nonresponse. Still, by systematically partitioning early brain changes into universal, placebo-mediated and drug-specific components, the study delivers what the field has lacked: a mechanistic map of how treatment for depression begins in the brain, weeks before the patient reports feeling better. It transforms the placebo from a statistical nuisance into a defined neural process, and it moves precision psychiatry a tangible step closer to the clinic.

Subject of Research: Early treatment-induced changes in brain functional connectivity in major depressive disorder following antidepressant or placebo administration

Article Title: Early brain functional connectivity changes induced by antidepressants and placebo

Article References: Tong, X., Fonzo, G. A., Carlisle, N. B., Xie, H., Berdichevsky, Y., Keller, C. J., Oathes, D. J., Nemeroff, C. B., Lin, F. V., & Zhang, Y. (2026). Early brain functional connectivity changes induced by antidepressants and placebo. Nature Mental Health. https://doi.org/10.1038/s44220-026-00729-y

Image Credits: AI Generated

DOI: 10.1038/s44220-026-00729-y

Keywords: major depressive disorder, functional connectivity, antidepressants, placebo effect, sertraline, escitalopram, machine learning, resting-state fMRI, EMBARC, CAN-BIND, biomarkers, precision psychiatry

The trial enrolled 262 patients with symptomatic paroxysmal or persistent atrial fibrillation and randomised them in a 2:1 ratio to pulmonary vein isolation or to a sham procedure. The primary endpoint was the between-group difference in the change from baseline to six months in the AFEQT summary score, a well-established questionnaire measuring atrial fibrillation-related quality of life. At six months, the mean AFEQT score improved from 61 to 81 in the ablation group and from 59 to 75 in the sham group. Both improvements were clinically meaningful, but the difference in change between the groups was not statistically significant. Meanwhile, ablation demonstrated clear objective efficacy: atrial fibrillation was detected in 21 percent of ablated patients versus 41 percent of sham patients, an absolute difference of 20 percent, with a favourable safety profile.

What distinguishes PVI-SHAM-AF from earlier research is the rigor of its control condition. The sham intervention was not an inert experience but an active clinical pathway encompassing hospital admission, deep sedation and analgesia, venous access, a stay in the catheterization laboratory, cardioversion for patients who arrived in atrial fibrillation, and structured follow-up. The trial therefore tested catheter ablation against this comprehensive procedural and clinical-care package, not against no treatment at all. The investigators emphasise that the study did not evaluate conventional non-invasive ambulatory care. Within the six-month observation window, however, the superior rhythm control achieved by ablation simply did not translate into a statistically significant improvement in patient-reported quality of life beyond what the active sham pathway delivered.

Compared with the two previous sham-controlled ablation trials, SHAM-PVI and PFA-SHAM, PVI-SHAM-AF was substantially larger, exceeding the combined sample size of both predecessors. Baseline quality of life was impaired to a similar degree as in the major open-label trials CABANA and EARLY-AF. Intriguingly, while the improvement within the ablation arms was broadly consistent across all these studies, the improvement observed in the sham arm of PVI-SHAM-AF was markedly lower than in SHAM-PVI and PFA-SHAM. The editorial authors suggest this discrepancy indicates that patient management in PVI-SHAM-AF may have been more comprehensive than in the other two sham trials, intensifying the care received by the control group and thereby narrowing the apparent treatment effect on symptoms.

The findings echo a broader pattern in cardiovascular medicine. Previous reports have documented clinically relevant placebo effects in randomised trials of invasive procedures across settings as varied as resistant hypertension, percutaneous coronary intervention and vertebroplasty for osteoporotic vertebral fractures. A systematic review and meta-analysis found that only about a third of placebo-controlled trials of cardiovascular interventions demonstrated significant superiority of the invasive procedure over placebo. Against this backdrop, PVI-SHAM-AF is less an outlier than a striking confirmation that subjective, patient-reported endpoints are acutely susceptible to contextual healing, expectation and the attention that accompanies any hospital-based intervention.

Why did both groups improve so substantially? The editorial points to a likely combination of placebo and Hawthorne effects, regression to the mean, and optimised concomitant care driven by protocol-adherent assessments and intensive follow-up. Symptoms in atrial fibrillation, the authors argue, may not be determined solely by arrhythmia physiology but also by symptom perception, atrial or ventricular ectopy, anxiety and depression. Quantifying the individual contributions of these mechanisms is difficult, and PVI-SHAM-AF was not designed to isolate them. Disentangling how much of the improvement stems from the procedure itself, from heightened clinical attention, or from psychological factors remains a critical objective for future research and could reshape how symptom-directed therapies are evaluated.

Do the results mean ablation fails to relieve symptoms, or that it should be withheld from patients with preserved left ventricular function? The editorial authors firmly reject both conclusions. The trial demonstrates that ablation reduces atrial fibrillation recurrence and burden safely, and it does not challenge indications in settings where reducing arrhythmia burden may improve clinically relevant outcomes, such as tachycardia-induced or atrial fibrillation-aggravated cardiomyopathy and heart failure with reduced ejection fraction, populations that were not the focus of this study. The results are confined to patient-reported outcomes rather than morbidity or mortality, reflecting a familiar divergence in cardiology where effects on hard endpoints and on how patients feel can part ways, as seen with beta-blockers, inotropes and implantable cardioverter-defibrillators in heart failure.

Questions about patient selection and follow-up duration also deserve scrutiny. Data on the 937 patients who declined randomisation were insufficient for comparison, and willingness to accept an invasive sham procedure may have selected individuals with particular symptom burdens, expectations or treatment preferences; patients with severe symptoms might have declined to guarantee receiving ablation. Yet the mean baseline AFEQT score of 60 mirrored those in CABANA, EARLY-AF and STOP AF First, beta-blocker use remained high and balanced between groups, and no treatment effect heterogeneity by baseline score was observed. The six-month primary endpoint was chosen deliberately to minimise the impact of repeat procedures, but the authors concede it may have been too short to capture the full treatment effect, and it does not exclude longer-term benefits in rhythm control, medication use, healthcare utilisation or clinical outcomes. Twelve-month follow-up is ongoing.

For clinical practice, the implications centre on shared decision-making. PVI-SHAM-AF shows that the objective rhythm-control benefits of catheter ablation should be clearly distinguished from its effects on patient-reported quality of life at six months, information that is essential for counselling patients whose primary goal is symptom relief. The results also underscore the therapeutic power of comprehensive, attentive clinical care. Crucially, the authors stress that invasive sham procedures are research tools for delineating true treatment effects and must never be translated into clinical practice. Instead, the challenge is to identify which components of the sham-associated care pathway improved symptoms and how those elements can be incorporated into routine, non-invasive care.

Perhaps the trial’s most enduring lesson is methodological. The editorial demonstrates that randomised, blinded evaluation of an established, guideline-recommended invasive procedure is accepted by patients, accepted by many expert physicians, and feasible across multiple centres and countries. Sham-controlled designs are particularly important when evaluating subjective or patient-reported outcomes, because such endpoints are vulnerable to placebo effects, expectations, regression to the mean and the effects of intensified clinical care. Just as placebo controls are indispensable for drug therapies, the incremental effect of an invasive or surgical procedure on how patients feel cannot be reliably determined without an appropriate sham control. PVI-SHAM-AF may thus be remembered less for what it says about ablation alone and more for how it resets the standard of evidence for procedural medicine.

Subject of Research: A sham-controlled randomised trial evaluating catheter ablation for symptom relief and rhythm control in patients with symptomatic atrial fibrillation.

Article Title: PVI-SHAM-AF: what does this trial tell us about catheter ablation and symptoms in patients with atrial fibrillation?

Article References: Laufs, U., Böhm, M., Mahfoud, F., & Wachter, R. (2026). PVI-SHAM-AF: what does this trial tell us about catheter ablation and symptoms in patients with atrial fibrillation?. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03016-z

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03016-z

Keywords: atrial fibrillation, catheter ablation, pulmonary vein isolation, sham-controlled trial, quality of life, AFEQT score, placebo effect, rhythm control, patient-reported outcomes, PVI-SHAM-AF, cardiology, clinical trial